APAC Gamma Knife Market

Asia Pacific Gamma Knife Market Size (2024 to 2029)

The Size of the Gamma Knife Market in the Asia Pacific is valued at USD 71.33 million in 2024 and is estimated to grow at a CAGR of 9.63%, to reach USD 112.95 million by 2029.

Due to the increasing incidence of cancer and obesity and the aging population, the Asia Pacific Gamma Knife market is booming. Furthermore, the rise in the number of efforts made by various government organizations, the growing number of people with neurological disorders, and the enhanced features of Gamma Knife systems are propelling the market forward. Another key growth-boosting aspect is an increasing understanding of the technology involved in the operation and the appealing advantages it offers over open surgeries.

The market for gamma knife therapy in neurological treatment is likely to rise because of its advantages over traditional surgeries. Because it is a non-invasive procedure, it provides greater safety, minor injury to surrounding tissues, and pinpoint precision when treating target cells in the brain. The market is likely to drive by increased usage of these instruments in surgery centers due to the rising prevalence of neurological diseases and the growing desire for minimally invasive treatments. The Leksell Gamma Knife Icon, which was recently invented, is in high demand, and there is a greater need for this technology to be developed.

The market's growth is hampered by strict regulatory standards, a lengthy licensing process for Gamma Knife systems, expensive implementation costs, and the scarcity of experienced professionals. Furthermore, the expense of treatment is highly significant. As a result, the majority of people cannot afford it. The tumor's severity also determines the expense of treatment. 

This research report on the APAC Gamma Knife Market has been segmented and sub-segmented into the following categories.

By Disease Indication

• Brain Metastasis
• Cancer
• Trigeminal Neuralgia
• AVM
• Others

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Asia Pacific is expected to have the most significant CAGR during the forecast period because of the rising implementation of gamma knife surgical technology, also contributing to the expansion of this area in the gamma knife market is an increase in the number of patients with cancer and brain tumors, as well as improved healthcare technologies, particularly in emerging countries.

The China gamma knife market is witnessing significant growth due to expanding population, rising disposable income, an aging population, and rising awareness levels. As a result, the Asian market attracts more new entrants than the developed world.

The Japan gamma knife market has the highest revenue share in this region. Japan is the world's second-largest market in terms of volume. Increased disease and the growing use of gamma knife tools in surgery centers contribute to its domination.

The India gamma knife market is the fastest-growing region because of the increased use of high-cost, technologically advanced products. Due to the rising approval of gamma knife treatment systems, the Asia Pacific gamma knife market is likely to reach significantly throughout the forecast period.

For example, the China Food and Drug Administration (CFDA) approved Elekta's Leksell Gamma Knife Icon radiosurgery system in 2018, allowing healthcare practitioners to deliver this advanced technology to Chinese patients.

KEY MARKET PLAYERS

Top companies leading in the APAC Gamma Knife Market profiled in the report are Cyber Medical Corporation Ltd., ET Medical group and American Shared Hospital Services, Masep Infini Asia Pacific, Inc., Hokai, Nordion Inc, Huiheng Medical Inc, Elekta AB, Varian Medical Systems.,